Nuvation Bio Inc. is trading at $5.19 (0.4%) up today after RBC Capital raised its price target to $20, citing optimism around its glioma drug potential.
- RBC Capital increased its price target from $13 and reaffirmed an Outperform rating on June 4.
- The stock continues to show strength following a significant move in the previous session, outperforming a softer broader market.
- Analysts highlighted the clinical potential of the company's glioma treatment as the primary driver for the valuation hike.